–
(CercleFinance.com) – NFL Biosciences shares rose on Friday morning following the announcement of the capital increase of GB Holding by businessman Grard Leduc, a well-known entrepreneur in the pharmaceutical sector. title of the biopharmaceutical company, which develops botanical drugs for the treatment of addictions and addictions, currently takes almost 3% while the Parisian market is progressing by about 0.7%.
GB Holding exercised 100,000 share subscription warrants (BSA), bringing its stake to approximately 11.2% of the capital of NFL Biosciences, a level that the businessman has undertaken to maintain for a period of at least nine months. NFL recalls that Grard Leduc notably founded, directed and sold Ethypharm, a European pharmaceutical laboratory specializing in pathologies of the central nervous system (CNS) and hospital injectables which had more than 800 employees.
‘Addiction products have always been of great interest to me,’ he explained. ‘NFL-101, for smoking cessation, is a potentially revolutionary product with a whole new mechanism of action,’ added the entrepreneur. 101 in smoking cessation are expected in the 3rd and 4th quarters of 2023.Copyright (c) 2023 CercleFinance.com. All rights reserved.
2023-06-30 08:39:42
#NFL #Biosciences #Holding #monte #capital
